Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07778888
PHASE2
BL1107 Response and Intensity Guided Dosing for Hyperemia Resolution Trial
Sponsor: Bausch & Lomb Incorporated
View on ClinicalTrials.gov
Summary
Trial RX01-BL1107-1202 is designed to identify the lowest effective concentration of BL1107 required for complete resolution of conjunctival hyperemia in participants with DED. Participants will be masked to concentration of BL1107 received.
Official title: Phase 2a Masked Trial to Identify the Lowest Effective Concentration of BL1107 for Conjunctival Hyperemia in Patients With Dry Eye Disease
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2026-10
Completion Date
2027-02
Last Updated
2026-08-21
Healthy Volunteers
No
Conditions
Interventions
DRUG
BL1107
BL1107 topical ocular solution